Diagnosticos da AmericaBSP:DASA3 -1.42%46 EBITDA Margin % is 25.92% as of Mar. 2026, which is 60% above its 10-year median of 16.21. GuruFocus rates BSP:DASA3 with a GF Score™ of 46/100 and a GF Value™ of R$1.70 (Significantly Overvalued). The stock has 3 warning signs investors should review. Among 204 Medical Diagnostics & Research companies, Diagnosticos da America ranks better than 74.02% on this metric.
Diagnosticos da America (BSP:DASA3) EBITDA Margin % Explanation
EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Diagnosticos da America EBITDA Margin % Related Terms
Diagnosticos da America EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BSP:DASA3 vs TMO, DHR, IDXX: EBITDA Margin % Comparison
For the Diagnostics & Research subindustry, Diagnosticos da America's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnosticos da America EBITDA Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnosticos da America's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Diagnosticos da America's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnosticos da America (BSP:DASA3) has a EBITDA Margin % of 25.92% as of Mar. 2026. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Diagnosticos da America and its competitors. This is 60% above median its historical median of 16.21. Over the past decade, Diagnosticos da America's EBITDA Margin % has ranged from 10.35 to 20.23. According to the industry distribution chart, Diagnosticos da America ranks #53 out of 204 companies in the Medical Diagnostics & Research industry, placing it in the top 26%.
Is Diagnosticos da America's EBITDA Margin % too high?
Diagnosticos da America's current EBITDA Margin % of 25.92% is 60% above median its 10-year median of 16.21. Over the past 10 years, this metric has ranged from a low of 10.35 to a high of 20.23. The Medical Diagnostics & Research industry median EBITDA Margin % is 5.20. Diagnosticos da America's value of 25.92% is 398.5% above this industry median. Based on the distribution chart, Diagnosticos da America ranks #53 out of 204 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diagnosticos da America has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Diagnosticos da America's EBITDA Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnosticos da America ranks #53 out of 204 companies for EBITDA Margin %. This puts Diagnosticos da America in the upper half of its industry. The industry median EBITDA Margin % is 5.20. Diagnosticos da America's value of 25.92% is 398.5% above this benchmark. Historically, Diagnosticos da America's own EBITDA Margin % has ranged from 10.35 to 20.23 over the past decade. While the company's 10-year median is 16.21 vs. the industry median of 5.20, Diagnosticos da America has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Medical Diagnostics & Research company?
The median EBITDA Margin % among Medical Diagnostics & Research companies is 5.20, based on 204 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnosticos da America's current EBITDA Margin % of 25.92% is 398.5% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Diagnosticos da America and its competitors. For the Medical Diagnostics & Research industry, the median EBITDA Margin % is 5.20 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnosticos da America's current EBITDA Margin % is 25.92%, which is 60% above median its own 10-year median of 16.21. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnosticos da America stock overvalued right now?
Based on GuruFocus' analysis, Diagnosticos da America (BSP:DASA3) is currently considered Significantly Overvalued. The stock's GF Value™ is R$1.70, compared to a current price of R$2.78 — trading 63.5% above its estimated fair value. The current EBITDA Margin % is 25.92%, which is 60% above median its 10-year median of 16.21 and 398.5% above the Medical Diagnostics & Research industry median of 5.20. Diagnosticos da America's overall GF Score™ is 46/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Diagnosticos da America (BSP:DASA3), the current EBITDA Margin % is 25.92% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Diagnosticos da America (BSP:DASA3) Overvalued in 2026?
Based on GuruFocus' analysis, Diagnosticos da America stock appears to be overvalued.
The current stock price of R$2.78 is trading 63.5% above its estimated GF Value™ of R$1.70.
GuruFocus considers Diagnosticos da America to be Significantly Overvalued.
Key valuation signals for BSP:DASA3:
EBITDA Margin %: 25.92% (60% above median its 10-year median of 16.21)
GF Value™: R$1.70 vs. price of R$2.78 (63.5% above fair value)
Industry Position: 398.5% above the Medical Diagnostics & Research median (#53 of 204)
No single metric tells the full story. See the BSP:DASA3 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Diagnosticos da America SA operates as a medical diagnostics company in Brazil. The company offers clinical analysis, diagnostic imaging tests, and patient service centers. It has three operating segments. Outpatient care services and care coordination includes Diagnosis and health management, Hospitals and oncology include Medical and hospital services & Foreign operations include Diagnosis. The majority is from the Hospitals and oncology segment. Geographically, it operates in Brazil and South America (Argentina, Uruguay, Chile and Colombia).
46GF Score
Get the complete analysis for BSP:DASA3
EBITDA Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BSP:DASA3 has been successfully added to your 
